Latest News and Press Releases

Amphista Therapeutics to present novel mechanism of action for the degradation of BRD9 using its proprietary Targeted Glue® technology at two key upcoming scientific conferences Oral presentations...

NurExone Biologic Enhances Visibility in Pharmaceutical Industry with Technological Presentations at Major Global Events

Crescendo Biologics to present at the 2024 AACR Annual Meeting Cambridge, UK, 6 March 2024 – Crescendo Biologics Ltd (Crescendo), a clinical stage, immuno-oncology company developing novel, targeted...

         PRESS RELEASE Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders First...

         PRESS RELEASE Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders First...

Statement from Dr. Jonathan Milner on the suspension of the “Vote AGAINST” campaign CAMBRIDGE, England, 1 November 2023 - Jonathan Milner, the founder and one of the largest investors in Abcam plc...

Arecor Therapeutics plc(“Arecor” or the “Group”) BUSINESS UPDATE Strong pipeline of revenue-generating collaborations with major pharmaceutical and biotech companies with further deals anticipated...

– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues – ...

Business simulation coding contest takes place in world-class universities in the UK: Oxford, Cambridge and Imperial College, offering €30,000 grand prize Top 3 Oxford students received their prizes...

SRF388 clinical program advancing well; updated clinical data expected in the first half of 2023 First patient dosed in a Phase 1/2 study evaluating SRF114, a potential best-in-class anti-CCR8...